Characteristics of patients eligible for PEGASUS in the ACTION Registry–GWTG by P2Y12 use 1 year after MI
| Characteristics |
Overall cohort (n=83 871) |
On DAPTat1 year post-MI (n=23 042) |
NoDAPT 1 year post-MI (n=60 829) | p Value |
| Patient demographics | ||||
| Age, mean (SD) | 69.4 (9.5) | 69.3 (9.0) | 69.4 (9.6) | 0.03 |
| Men, n (%) | 51 117 (60.9) | 14 165 (61.5) | 36 952 (60.7) | 0.06 |
| Race, n (%) | ||||
| White | 73 232 (87.3) | 20 562 (89.2) | 52 670 (86.6) | <0.001 |
| African-American | 8067 (9.6) | 1 858 (8.1) | 6209 (10.2) | <0.001 |
| Asian | 1525 (1.8) | 390 (1.7) | 1135 (1.9) | 0.09 |
| Other | 1047 (1.3) | 232 (1.0) | 815 (1.3) | <0.001 |
| Hispanic or Latino, n (%) | 4415 (5.3) | 1066 (4.6) | 3349 (5.5) | <0.001 |
| Insurance, n (%) | ||||
| None | 6037 (7.2) | 672 (2.9) | 5365 (8.8) | <0.001 |
| Private | 21 176 (25.2) | 7069 (30.7) | 14 107 (23.2) | <0.001 |
| Medicaid or Medicare | 55 595 (66.3) | 15 127 (65.6) | 40 468 (66.5) | 0.02 |
| Other | 1063 (1.3) | 174 (0.8) | 889 (1.5) | <0.001 |
| Patient medical history | ||||
| Body mass index, mean (SD) | 29.4 (9.4) | 29.7 (10.4) | 29.3 (9.0) | <0.001 |
| Diabetes, n (%) | 29 704 (35.4) | 7497 (32.5) | 22 207 (36.5) | <0.001 |
| Insulin therapy, n (%) | 6262 (7.5) | 1370 (5.9) | 4892 (8.0) | <0.001 |
| Hypertension, n (%) | 64 472 (76.9) | 17 196 (74.6) | 47 276 (77.7) | <0.001 |
| Dyslipidaemia, n (%) | 43 458 (51.8) | 11 941 (51.8) | 31 517 (51.8) | 0.98 |
| Current/recent smoker, n (%) | 23 253 (27.7) | 5948 (25.8) | 17 305 (28.4) | <0.001 |
| Cerebrovascular disease, n (%) | 3742 (4.5) | 882 (3.8) | 2860 (4.7) | <0.001 |
| Peripheral arterial disease, n (%) | 6401 (7.6) | 1465 (6.4) | 4936 (8.1) | <0.001 |
| Prior PCI, n (%) | 17 094 (20.4) | 4336 (18.8) | 12 758 (21.0) | <0.001 |
| Prior CABG, n (%) | 267 (0.3) | 58 (0.3) | 209 (0.3) | 0.04 |
| Prior MI, n (%) | 15 763 (18.8) | 3807 (16.5) | 11 956 (19.7) | <0.001 |
| Prior heart failure, n (%) | 5615 (6.7) | 996 (4.3) | 4619 (7.6) | <0.001 |
| Chronic kidney disease, n (%) | ||||
| Stage 1 or 2 | 57 663 (68.8) | 16 761 (72.7) | 40 902 (67.2) | <0.001 |
| ≥Stage 3 | 25 551 (30.5) | 6075 (26.4) | 19 476 (32.0) | <0.001 |
| Anaemia, n (%) | 19 062 (22.7) | 4115 (17.9) | 14 947 (24.6) | <0.001 |
| Chronic lung disease, n (%) | 9723 (11.6) | 2143 (9.3) | 7580 (12.5) | <0.001 |
| MI characteristics and management | ||||
| Presentation, n (%) | ||||
| STEMI | 33 609 (40.1) | 11 146 (48.4) | 22 463 (36.9) | <0.001 |
| NSTEMI | 50 262 (59.9) | 11 896 (51.6) | 38 366 (63.1) | <0.001 |
| PCI, n (%) | 55 973 (66.7) | 19 852 (86.2) | 36 121 (59.4) | <0.001 |
| DES | 37 510 (44.7) | 15 085 (65.5) | 22 425 (36.9) | <0.001 |
| BMS | 14 460 (17.2) | 3872 (16.8) | 10 588 (17.4) | 0.04 |
| CABG | 10 463 (12.5) | 949 (4.1) | 9514 (15.6) | <0.001 |
| Bleeding Risk Score, n (%) | ||||
| Very low | 12 262 (14.8) | 3529 (15.6) | 8733 (14.6) | <0.001 |
| Low | 42 931 (51.9) | 12 336 (54.4) | 30 595 (51.0) | <0.001 |
| Moderate | 24 291 (29.4) | 6226 (27.5) | 18 065 (30.1) | <0.001 |
| High | 2931 (3.6) | 546 (2.4) | 2385 (4.0) | <0.001 |
| Very high | 239 (0.3) | 43 (0.2) | 196 (0.3) | 0.001 |
| Discharge medications | ||||
| P2Y12 inhibitor, n (%) | ||||
| None | 19 111 (22.8) | 1238 (5.4) | 17 873 (29.4) | <0.001 |
| Clopidogrel | 51 075 (60.9) | 17 297 (75.1) | 33 778 (55.5) | <0.001 |
| Ticlopidine | 71 (0.1) | 19 (0.1) | 52 (0.1) | 0.89 |
| Prasugrel | 13 355 (15.9) | 4394 (19.1) | 8961 (14.7) | <0.001 |
| Ticagrelor | 375 (0.4) | 139 (0.6) | 236 (0.4) | <0.001 |
| Beta-blocker | 77 552 (92.5) | 21 559 (93.6) | 55 993 (92.0) | <0.001 |
| ACE inhibitor or ARB | 57 352 (68.4) | 16 539 (71.8) | 40 813 (67.1) | <0.001 |
| Statin | 77 181 (92.0) | 21 782 (94.5) | 55 399 (91.1) | <0.001 |
| Aspirin at any dose | 81 155 (96.8) | 22 548 (97.9) | 58 607 (96.3) | <0.001 |
| Medications at 1 year | ||||
| P2Y12 inhibitor | ||||
| None | 60 829 (72.5) | 0 (100.0) | 60 829 (100.0) | |
| Clopidogrel | 18 255 (21.8) | 18 255 (79.2) | 0 | |
| Ticlopidine | 9 (0.0) | 9 (0.0) | 0 | |
| Prasugrel | 4089 (4.9) | 4089 (17.7) | 0 | |
| Ticagrelor | 693 (0.8) | 693 (3.0) | 0 | |
| Anticoagulation | ||||
| Warfarin | 1832 (2.2) | 397 (1.7) | 1435 (2.4) | <0.001 |
| Dabigatran | 139 (0.2) | 41 (0.2) | 98 (0.2) | 0.59 |
| Rivaroxaban | 95 (0.1) | 20 (0.1) | 75 (0.1) | 0.16 |
| Apixiban | 4 (0.0) | 0 (0.0) | 4 (0.0) | 0.22 |
| Beta-blocker | 42 597 (50.8) | 17 723 (76.9) | 24 874 (40.9) | <0.001 |
| ACE inhibitor or ARB | 33 658 (40.1) | 13 994 (60.7) | 19 664 (32.3) | <0.001 |
| Statin | 41 273 (49.2) | 17 797 (77.2) | 23 476 (38.6) | <0.001 |
ACTION Registry–GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With The Guidelines; ARB, angiotensin II receptor blocker; BMS, bare-metal stent; CABG, coronary artery bypass grating; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation MI.